Former Medtronic CEO Bill George says he hopes the company will proceed with its controversial merger with Ireland-based Covidien.
The deal is subject to new U.S. Treasury department rules designed to make so-called tax inversion deals less financially attractive. Medtronic says it's studying the provisions.
The company would have to pay Covidien a so-called "break-up fee" of up to $850 million if Medtronic backs out.
But George says that won't be a major consideration as Medtronic decides how to proceed.
"That's 2 percent of the deal, of a $43 billion deal," George said. "The deal is worth a lot more value than that. It's going to produce a lot more profit than that in year one. So I don't think that is going to be the deciding factor here."
Medtronic's share price fell as much as 4 percent Tuesday following the Treasury department's Monday evening announcement of new provisions.
A tax inversion involves a U.S. firm merging with a foreign company, and reducing its US tax bill.
George spoke to The Daily Circuit's Tom Weber.
Before you keep reading ...
MPR News is made by Members. Gifts from individuals fuel the programs that you and your neighbors rely on. Donate today to power news, analysis, and community conversations for all.